Latest news with #bronchiectasis
Reuters
4 days ago
- Health
- Reuters
US FDA approves Insmed's lung disease drug
Aug 12 (Reuters) - The U.S. Food and Drug Administration has approved Insmed's (INSM.O), opens new tab oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition. Insmed's drug, branded as Brinsupri, targets non-cystic fibrosis bronchiectasis, a chronic lung condition characterized by permanently damaged airways, leading to persistent cough and excessive mucus production. It affects 350,000 to 500,000 adults in the U.S., according to the American Lung Association. Brinsupri works by blocking certain inflammatory enzymes in the white blood cells, preventing them from becoming overactive and damaging the lungs.
Bloomberg
4 days ago
- Health
- Bloomberg
Insmed Drug Wins First US Approval for Debilitating Lung Disease
US regulators have approved the first drug to treat a debilitating lung condition, ending two centuries of waiting and paving the way for a potential blockbuster from Insmed Inc. The once-daily pill, called Brinsupri and known chemically as brensocatib, eases bronchiectasis, a chronic inflammatory disease that damages the airways and can make it hard to breathe. Patients struggle to clear mucus from their lungs, which creates a breeding ground for infections and often lands them in the hospital for long periods.
Yahoo
04-08-2025
- Health
- Yahoo
The Hidden Lung Infection Impacting Millions: World NTM Day Puts Spotlight on Awareness
With Annual NTM Case Rates Rising, Patients and Providers Are Urged to Recognize the Symptoms and Risks MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the world prepares to observe World NTM Day on August 4, 2025, NTM Info & Research (NTMir) is calling on patients, physicians, caregivers, and policy leaders to shine a spotlight on nontuberculous mycobacterial (NTM) lung disease, a growing but underrecognized threat to global respiratory health. Experience the full interactive Multichannel News Release here: NTM lung disease is caused by environmental bacteria found in water and soil. While many are exposed, people with underlying lung conditions—particularly bronchiectasis—are at higher risk of infection. Alarmingly, new data show that NTM cases are rising by more than 8.2% annually, particularly among women over age 65 and individuals with chronic lung disease. The economic burden per patient can exceed $30,000 per year, underscoring the cost of delayed diagnosis and limited treatment options. "NTM lung disease is one of the most misunderstood and misdiagnosed conditions we see today," said Amy Leitman, JD, President of NTMir. "It doesn't just threaten lives—it disrupts them. But the earlier we recognize the symptoms, the better our chances of preventing severe lung damage and improving patient outcomes." Most people diagnosed with NTM also have bronchiectasis, a condition that causes permanent damage to the airways. When combined, the diseases can lead to a vicious cycle of recurring infections, declining lung function, and years of missed opportunities for proper care. "We want to empower people to listen to their lungs," said Leitman. "If someone is experiencing persistent coughing, fatigue, shortness of breath, or unexplained weight loss—don't wait. Ask your doctor if NTM could be the cause." World NTM Day: Raising Voices, Inspiring Action This year's theme, "Recognize. Respond. Rise Together," emphasizes the critical need for: Early diagnosis through improved screening protocols Patient education and community engagement Investment in research and innovation to support more effective and accessible treatments To that end, NTMir continues to lead efforts to: Deliver comprehensive educational resources on diagnosis, treatment, and ongoing clinical research Support a global network of patients and caregivers through online communities and local support groups Advocate for increased research funding and policy change to address the unmet needs of the NTM community Visit for patient stories, educational tools, clinical trial information, and ways to take action. How You Can Help: Learn the symptoms and risk factors by visiting Share social media posts, videos, and infographics using #WorldNTMDay2025 Join a support group or community event near you Encourage your healthcare providers to consider NTM in patients with unexplained respiratory symptoms Together, we can improve outcomes, expand awareness, and give a stronger voice to those living with NTM lung disease. About NTM Info & Research (NTMir):NTM Info & Research (NTMir) is a national 501(c)(3) non-profit organization formed on behalf of patients with pulmonary nontuberculous mycobacterial (NTM) disease for patient support, medical education and research. The organization serves patients, healthcare providers and researchers dealing with bronchiectasis and NTM. It advocates a broad agenda to promote early diagnosis, improved treatments, and research. The mission is to bring a voice to the concerns of all our constituents with government officials and agencies that guide, research, and regulate therapies developed to treat these diseases. NTM Info & Research recognizes the need for advancement in education and treatment of bronchiectasis. About World NTM Day 2025: World NTM Day, observed annually on August 4, is a global awareness initiative led by NTM Info & Research (NTMir) to spotlight the rising impact of nontuberculous mycobacterial (NTM) lung disease—a serious and often misunderstood condition that affects tens of thousands each year. The 2025 theme, "Recognize. Respond. Rise Together," underscores the urgent need to increase awareness, improve early detection, and empower patients and providers with knowledge. As NTM cases continue to climb and too many remain undiagnosed or misdiagnosed, World NTM Day calls on the global community to take action—by learning the signs, supporting those affected, and advancing research that brings hope for better outcomes. View original content: SOURCE NTM Info & Research (NTMir) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-07-2025
- Business
- Yahoo
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB). Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system. "With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis." "We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step." "We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area." AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties. About AATec Medical AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit and follow AATec on LinkedIn. About Northway Biotech Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit Northway Biotech Contact: Prof. Vladas Algirdas BumelisCEO and Chairman of the AATec Medical Contact: Dr. Rüdiger Jankowsky, CEOinfo@ Media Contact: MC ServicesKatja Arnold, Julia von Hummelaatec-medical@ Phone: +49 (0)89 2102280 SOURCE: Northway Biotech View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
BBC News
12-07-2025
- Sport
- BBC News
'It's never too late' - Endurance athlete, 77, urges pensioners to take on triathlons
A 77-year-old endurance sport athlete is spreading the message that it is never too late to try new Dockery, from Southville, Bristol, took up running at the age of 52 and began competing in triathlons in her next challenge is Sunday's Cotswold Classic, a triathlon event which involves cycling, swimming and running a total of 70.3 miles (113.1km)."I want others that are in their 50s, 60s and 70s to know that you are not past it," said Ms Dockery. "You can still do so much." Her journey into endurance sports began at the age of 52, while she was living in the United States, following a diagnosis of bronchiectasis - a lung condition in which the airways become damaged and widened, making it harder to clear though the case was, doctors encouraged her to run to strengthen her lungs."I did not like [running] at all," she admitted." I thought it was really boring."But a year later, the social aspect changed everything."It was because of the people. The people you meet whilst running are fantastic."They support you, they cheer you on," she was the sense of community that led her to enter her first race and at 62, she competed in her first triathlon."I thought I was too old until a friend in her 70s encouraged me to try. I loved it," said Ms Dockery."The triathlon community is so welcoming. I'd arrive not knowing anyone and leave with a new little family who encouraged me."Now, preparing for another major challenge, she admitted "I'm terrified, but I know I'll enjoy it. I've trained hard. The only worry is the heat." When she was younger, Ms Dockery said she thought of 40 as old. "Even now, I meet people in their 40s and 50s who believe it's too late for them. "When I tell them I started running at 52 and did my first triathlon in my 60s, they're encouraged."Sometimes I still feel inhibited. But most people are so kind. I'm very lucky," she added.
